These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 11468999)

  • 1. [Safety and effectiveness fully standardized. Hexavalent vaccine can close vaccination gaps].
    MMW Fortschr Med; 2001 Jun; 143(25):51-3. PubMed ID: 11468999
    [No Abstract]   [Full Text] [Related]  

  • 2. [Hexavalent vaccines facilitate compliance. Vaccination calendars become significantly simpler].
    MMW Fortschr Med; 2002 Jan; 144(1-2):68. PubMed ID: 11847892
    [No Abstract]   [Full Text] [Related]  

  • 3. A population-based, postlicensure evaluation of the safety of a combination diphtheria, tetanus, acellular pertussis, hepatitis B, and inactivated poliovirus vaccine in a large managed care organization.
    Zangwill KM; Eriksen E; Lee M; Lee J; Marcy SM; Friedland LR; Weston W; Howe B; Ward JI
    Pediatrics; 2008 Dec; 122(6):e1179-85. PubMed ID: 19047220
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety, reactogenicity and immunogenicity of a combined hexavalent tetanus, diphtheria, acellular pertussis, hepatitis B, inactivated poliovirus vaccine and Haemophilus influenzae type b conjugate vaccine, for primary immunization of infants.
    Zepp F; Knuf M; Heininger U; Jahn K; Collard A; Habermehl P; Schuerman L; Sänger R
    Vaccine; 2004 Jun; 22(17-18):2226-33. PubMed ID: 15149781
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Hexavalent vaccines evaluated in general practice. High compliance, good tolerance].
    MMW Fortschr Med; 2003 Nov; 145(48):58-9. PubMed ID: 14725004
    [No Abstract]   [Full Text] [Related]  

  • 6. FDA licensure of diphtheria and tetanus toxoids and acellular pertussis adsorbed, hepatitis B (recombinant), and poliovirus vaccine combined, (PEDIARIX) for use in infants.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2003 Mar; 52(10):203-4. PubMed ID: 12653460
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and immunogenicity of a hexavalent diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine at 2, 3, 4, and 12-14 months of age.
    Halperin SA; Tapiero B; Diaz-Mitoma F; Law BJ; Hoffenbach A; Zappacosta PS; Radley D; McCarson BJ; Martin JC; Brackett LE; Boslego JW; Hesley TM; Bhuyan PK; Silber JL
    Vaccine; 2009 Apr; 27(19):2540-7. PubMed ID: 19124057
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Response of preterm newborns to immunization with a hexavalent diphtheria-tetanus-acellular pertussis-hepatitis B virus-inactivated polio and Haemophilus influenzae type b vaccine: first experiences and solutions to a serious and sensitive issue.
    Omeñaca F; Garcia-Sicilia J; García-Corbeira P; Boceta R; Romero A; Lopez G; Dal-Ré R
    Pediatrics; 2005 Dec; 116(6):1292-8. PubMed ID: 16322149
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Concomitant use of the 3-dose oral pentavalent rotavirus vaccine with a 3-dose primary vaccination course of a diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio-Haemophilus influenzae type b vaccine: immunogenicity and reactogenicity.
    Ciarlet M; He S; Lai S; Petrecz M; Yuan G; Liu GF; Mikviman E; Heaton PM; Panzer F; Rose T; Koller DY; Van Damme P; Schödel F
    Pediatr Infect Dis J; 2009 Mar; 28(3):177-81. PubMed ID: 19209092
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenicity and reactogenicity of two regimens of diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio and Haemophilus influenzae type b vaccines administered to infants primed at birth with hepatitis B vaccine.
    Cheng HK; Rajadurai VS; Amin Z; Sriram B; Yee MF; Han HH; Bock HL; Safary A
    Southeast Asian J Trop Med Public Health; 2004 Sep; 35(3):685-92. PubMed ID: 15689088
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Basic immunization hexvalent vaccine. Are there differences between vaccines?].
    MMW Fortschr Med; 2003 May; 145(19):54. PubMed ID: 12813984
    [No Abstract]   [Full Text] [Related]  

  • 12. Safety of DTaP-IPV-HIb-HBV hexavalent vaccine in very premature infants.
    Faldella G; Galletti S; Corvaglia L; Ancora G; Alessandroni R
    Vaccine; 2007 Jan; 25(6):1036-42. PubMed ID: 17088013
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunogenicity and safety of a DTaP-IPV//PRP-T vaccine (Pentaxim) booster during the second year of life in Thai children primed with an acellular pertussis combined vaccine.
    Thisyakorn U; Pancharoen C; Chuenkitmongkol S; Ortiz E
    Southeast Asian J Trop Med Public Health; 2009 Mar; 40(2):282-94. PubMed ID: 19323013
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Unexplained cases of sudden infant death shortly after hexavalent vaccination.
    Zinka B; Rauch E; Buettner A; Ruëff F; Penning R
    Vaccine; 2006 Jul; 24(31-32):5779-80. PubMed ID: 15908063
    [No Abstract]   [Full Text] [Related]  

  • 15. Antipolyribosyl ribitol phosphate response of premature infants to primary and booster vaccination with a combined diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio virus/Haemophilus influenzae type b vaccine.
    Omeñaca F; Garcia-Sicilia J; García-Corbeira P; Boceta R; Torres V
    Pediatrics; 2007 Jan; 119(1):e179-85. PubMed ID: 17145903
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comment on B. Zinka et al., Unexplained cases of sudden infant death shortly after hexavalent vaccination.
    von Kries R
    Vaccine; 2006 Jul; 24(31-32):5783-4; author reply 5785-6. PubMed ID: 16081190
    [No Abstract]   [Full Text] [Related]  

  • 17. PEDIARIX: clinical trials.
    Yeh SH
    Expert Rev Vaccines; 2005 Apr; 4(2):139-45. PubMed ID: 15889985
    [TBL] [Abstract][Full Text] [Related]  

  • 18. B. Zinka et al., Unexplained cases of sudden infant death shortly after hexavalent vaccination.
    Schmitt HJ; Siegrist CA; Salmaso S; Law B; Booy R
    Vaccine; 2006 Jul; 24(31-32):5781-2; author reply 5785-6. PubMed ID: 16084630
    [No Abstract]   [Full Text] [Related]  

  • 19. Safety and immunogenicity of a primary course and booster dose of a combined diphtheria, tetanus, acellular pertussis, hepatitis B and inactivated poliovirus vaccine.
    Meriste S; Lutsar I; Tamm E; Willems P
    Scand J Infect Dis; 2006; 38(5):350-6. PubMed ID: 16709537
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined reduced-antigen-content diphtheria-tetanus-acellular pertussis and polio vaccine (dTpa-IPV) for booster vaccination of adults.
    Grimprel E; von Sonnenburg F; Sänger R; Abitbol V; Wolter JM; Schuerman LM
    Vaccine; 2005 May; 23(28):3657-67. PubMed ID: 15882526
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.